These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1479050)

  • 1. Fluoxetine: activating and sedating effects at multiple fixed doses.
    Beasley CM; Sayler ME; Weiss AM; Potvin JH
    J Clin Psychopharmacol; 1992 Oct; 12(5):328-33. PubMed ID: 1479050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine: activating and sedating effects.
    Beasley CM; Potvin JH
    Int Clin Psychopharmacol; 1993; 8(4):271-5. PubMed ID: 8277147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluoxetine versus trazodone: efficacy and activating-sedating effects.
    Beasley CM; Dornseif BE; Pultz JA; Bosomworth JC; Sayler ME
    J Clin Psychiatry; 1991 Jul; 52(7):294-9. PubMed ID: 2071559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression.
    Beasley CM; Sayler ME; Bosomworth JC; Wernicke JF
    J Clin Psychopharmacol; 1991 Jun; 11(3):166-74. PubMed ID: 2066455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
    Tollefson GD; Birkett M; Koran L; Genduso L
    J Clin Psychiatry; 1994 Oct; 55 Suppl():69-76; discussion 77-8. PubMed ID: 7961535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.
    Stark P; Hardison CD
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):53-8. PubMed ID: 3882682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
    Tollefson GD; Holman SL; Sayler ME; Potvin JH
    J Clin Psychiatry; 1994 Feb; 55(2):50-9. PubMed ID: 8077155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression.
    Beasley CM; Bosomworth JC; Wernicke JF
    Psychopharmacol Bull; 1990; 26(1):18-24. PubMed ID: 2196623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two dosage regimens of fluoxetine in major depression.
    Rickels K; Smith WT; Glaudin V; Amsterdam JB; Weise C; Settle GP
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):38-41. PubMed ID: 3882680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder.
    Cohn JB; Wilcox C
    J Clin Psychiatry; 1985 Mar; 46(3 Pt 2):26-31. PubMed ID: 3882677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
    Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
    Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of morning versus evening fluoxetine administration.
    Usher RW; Beasley CM; Bosomworth JC
    J Clin Psychiatry; 1991 Mar; 52(3):134-6. PubMed ID: 2005078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose.
    Beasley CM; Nilsson ME; Koke SC; Gonzales JS
    J Clin Psychiatry; 2000 Oct; 61(10):722-8. PubMed ID: 11078032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression.
    Tollefson GD; Rampey AH; Beasley CM; Enas GG; Potvin JH
    J Clin Psychopharmacol; 1994 Jun; 14(3):163-9. PubMed ID: 8027412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
    Feighner JP; Gardner EA; Johnston JA; Batey SR; Khayrallah MA; Ascher JA; Lineberry CG
    J Clin Psychiatry; 1991 Aug; 52(8):329-35. PubMed ID: 1907963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fixed-dose clinical trial of fluoxetine in outpatients with major depression.
    Fabre LF; Putman HP
    J Clin Psychiatry; 1987 Oct; 48(10):406-8. PubMed ID: 3312176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose.
    Fava M; Rappe SM; Pava JA; Nierenberg AA; Alpert JE; Rosenbaum JF
    J Clin Psychiatry; 1995 Feb; 56(2):52-5. PubMed ID: 7852252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.
    Feiger AD; Heiser JF; Shrivastava RK; Weiss KJ; Smith WT; Sitsen JM; Gibertini M
    J Clin Psychiatry; 2003 Mar; 64(3):243-9. PubMed ID: 12716264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evidence for 20mg a day of fluoxetine as the optimal dose in the treatment of depression.
    Altamura AC; Montgomery SA; Wernicke JF
    Br J Psychiatry Suppl; 1988 Sep; (3):109-12. PubMed ID: 3074862
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparative trial of fluoxetine and amitriptyline in patients with major depressive disorder.
    Feighner JP
    J Clin Psychiatry; 1985 Sep; 46(9):369-72. PubMed ID: 3897204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.